Home / Business and Economy / Granules India Profit Surges 40% on New Drug Sales
Granules India Profit Surges 40% on New Drug Sales
2 Nov
Summary
- Second-quarter profit rose by nearly 40% to 1.82 billion rupees.
- New product launches boosted sales significantly overseas.
- Higher production costs were offset by strong medicine performance.
Indian pharmaceutical company Granules India announced a nearly 40% increase in its second-quarter profit. Consolidated net profit for the period ending September 30 climbed to 1.82 billion rupees, a notable rise from the 1.31 billion rupees recorded in the same quarter last year.
This substantial profit growth was primarily driven by the successful introduction of new products. Furthermore, strong sales performance of the company's existing key medicines in significant overseas markets played a crucial role. These factors collectively managed to counteract the impact of escalating production costs.
The company's strategic focus on expanding its product portfolio and strengthening its presence in international territories appears to be yielding positive financial outcomes, as evidenced by this latest quarterly report.
